Haselmeier is pleased to announce that Berlin Chemie / Menarini, Berlin Germany has launched the BerliPen areo® 2 for insulin treatment.
The BerliPen areo® 2 is a joint development of Berlin Chemie / Menarini and Haselmeier GmbH. The new insulin pen combines technical superiority with elegant design and has been described as “Simple-Beautiful-Safe”. Its technology enables a safe and comfortable injection for patients and features non-moving outer components, very low injection force and easy dose adjustment. The design is styled for patients of any age and is available in four different colours: red, blue, green and black.
According to Michael Bollessen, Head of Marketing for Diabetes and OTC Products, “Our long-term collaboration with Haselmeier proved to be a great asset to Berlin Chemie / Menarini’s success. Both project teams worked hand in hand over several months in order to make this new pen a reality. Haselmeier with its creativity, flexibility and fast reaction times contributed a great deal to the timely launch.”
Volker Wirth, Director Sales and Marketing at Haselmeier added that “Haselmeier is delighted to collaborate on such a value-added partnership with Berlin Chemie / Menarini and contribute to their successful market introduction.”
Haselmeier is a leading designer and manufacturer of pen and auto-injection systems. The Company’s devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world.
Twitter